泰瓦公司以7亿美元收购Emalex, 以增加图雷特综合征药物ecopipam. Teva to buy Emalex for $700M to add Tourette syndrome drug ecopipam.

德华制药公司同意以7亿美元收购Emalex生物科学, Teva Pharmaceuticals has agreed to acquire Emalex Biosciences for $700 million, with potential additional payments. 这笔交易将Ecopipam,一种图雷特综合征治疗药物加入Teva的产品组合. The deal adds ecopipam, a Tourette syndrome treatment, to Teva's portfolio. 该公司预计将在2026年提交新的药物申请,并在当年的第三季度完成收购. The company expects to submit a new drug application in 2026 and close the acquisition by the third quarter of that year.